Director, Epidemiology

1 day ago

Menlo Park, California, United States Verantos Full time $120,000 - $180,000 per year

Overview

Located in California's Silicon Valley, Verantos is the global leader in high-validity real-world evidence at scale. By applying artificial intelligence to the complete patient record, Verantos enables life sciences organizations to generate high-validity evidence across therapeutic areas with measured accuracy, completeness, and traceability. Credible evidence accelerates clinical development, market access, medical affairs, pharmacovigilance, and regulatory initiatives.

Verantos believes that advanced RWE requires a group of dedicated and highly-trained professionals who are specialists in the field. Our team consists of physicians, data scientists, clinical researchers and engineers with a deep knowledge of, and extensive experience in, protocol development, health system engagement, electronic health record integration, de-identification, artificial intelligence, data enrichment, study implementation and validity assessment. In addition, we have vast experience within the healthcare ecosystem, including pharma, payer, provider, and regulatory.

Position Scope and Location 

You will work on advanced RWD/RWE projects with innovative biopharma companies and health systems to advance clinical research by leveraging our technology and expertise. Priorities include customer-facing and writing capabilities.

Major Responsibilities

→ Develop content required for execution and publication on projects that make significant contributions to science

  • Lead the development of protocols, statistical analysis plans, and requirements documents
  • Lead the development of abstracts and manuscripts related to studies, methods, and other efforts

→ Engage with key internal and external stakeholders

  • Coach and facilitate awareness of the appropriate use, timing, and implementation of epidemiologic methods and statistical techniques
  • Manage scientific discussions within customer and prospective customer meetings
  • Communicate significant scientific information to a variety of audiences

→ Execute scientifically-advanced projects

  • Demonstrate creative thought in applying methodological solutions that take advantage of advanced data sources and technologies
  • Leverage project management, product, and engineering resources to ensure timely deliverables
  • Collaborate with internal stakeholders to provide scientifically sound and efficient solutions to execution challenges

Position Requirements and Experience

Required

  • Doctoral degree in epidemiology
  • At least 5 years of professional experience within a pharmaceutical firm or working with pharmaceutical firms\
  • Excellent writing skills
  • Excellent verbal communication including the ability to interact with customers
  • Experience in the design, execution, and analysis of observational research
  • Creative intelligence, including a willingness to develop new methodologies that take advantage of a modern real-world evidence infrastructure using curation and data linkage

Preferred

  • Experience working for a data vendor, preferably a company specializing in electronic health record data
  • Experience working within an innovative growing startup company, including comfort with this culture
  • Experience performing at least one study using electronic health record unstructured data and artificial intelligence technologies
  • Record of publications in observational research
  • Clinical degree

Personal and Professional Characteristics

  • Meticulous
  • Technology savvy
  • Execution oriented
  • Collaborative
  • Communicative

  • Senior Director, Epidemiology

    3 weeks ago

    Florham Park, United States Shionogi Inc. in Full time

    Cascade global RWE vision into U.S. execution; ensure alignment across geographies (U.S., EU, Japan). Senior Director, Epidemiology & Real World Evidence (Finance) Overview The Senior Director, Global Epidemiology & Real-World Evidence (RWE) sets and drives the U.S. RWE strategy across therapeutic areas while ensuring alignment with global vision. Serving as...

  • Senior Director, Epidemiology

    2 weeks ago

    Florham Park, United States Shionogi Inc. (U.S.) Full time

    Senior Director, Epidemiology & Real World Evidence Direct message the job poster from Shionogi Inc. (U.S.) The Senior Director, Global Epidemiology & Real-World Evidence (RWE) sets and drives the U.S. RWE strategy across therapeutic areas while ensuring alignment with global vision. Serving as a methodological authority, the Senior Director directs large,...

  • Director, Portfolio Strategy

    1 week ago

    Menlo Park, United States Summit Corporation Full time

    Department: Business & Strategy Date Posted: 11/6/2025 Summary Location Menlo Park, CA, Princeton, NJ or Miami, FL onsite About Summit Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking...

  • Director, Portfolio Strategy

    2 weeks ago

    Menlo Park, United States Summit Corporation Full time

    Location: Menlo Park, CA, Princeton, NJ or Miami, FL onsite About Summit Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique...

  • Director, Portfolio Strategy

    2 weeks ago

    Menlo Park, United States Summit Therapeutics Sub, Inc. Full time

    Career Opportunities with Summit Therapeutics Sub, Inc. A great place to work. Careers At Summit Therapeutics Sub, Inc. Current job opportunities are posted here as they become available. Location: Menlo Park, CA, Princeton, NJ or Miami, FL onsite About Summit: Ivonescimab, known as SMT112, is a novel, potential first‑in‑class investigational bispecific...

  • Senior Manager/Associate Director, Portfolio Strategy

    2 weeks ago

    Menlo Park, United States Summit Therapeutics Sub, Inc. Full time

    Career Opportunities with Summit Therapeutics Sub, Inc. A great place to work. Careers At Summit Therapeutics Sub, Inc. Current job opportunities are posted here as they become available. Senior Manager, Portfolio Strategy & Market Research Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational bispecific antibody combining the...

  • Director, Portfolio Strategy

    1 week ago

    Menlo Park, CA, United States Summit Corporation Full time

    Department: Business & Strategy Date Posted: 11/6/2025 Summary Location Menlo Park, CA, Princeton, NJ or Miami, FL onsite About Summit Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking...

  • Director, Portfolio Strategy

    2 weeks ago

    Menlo Park, CA, United States Summit Therapeutics, Inc. Full time

    Location: Menlo Park, CA, Princeton, NJ or Miami, FL onsite About Summit Ivonescimab, known as SMT112, is a novel, potential firstinclass investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD1 with the antiangiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique...

  • Director, Portfolio Strategy

    4 days ago

    Menlo Park, CA, United States Summit Therapeutics, Inc. Full time

    Director, Portfolio Strategy & Market Research About Summit Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative...

  • Head of Business Continuity Planning

    2 weeks ago

    Menlo Park, CA, United States Summit Therapeutics Sub, Inc. Full time

    Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity when in the presence of both PD1 and VEGF. Summit has begun its clinical development of ivonescimab in nonsmall cell lung cancer (NSCLC), with three active Phase III trials: HARMONi is a Phase III clinical trial which intends to evaluate...